New research uncovers how cancers with common mutation develop resistance to targeted drugs

(Dana-Farber Cancer Institute) A new study by Dana-Farber Cancer Institute researchers has given scientists their first look at the genomic landscape of tumors that have grown resistant to drugs targeting the abnormal KRASG12C protein. Their work shows that, far from adopting a common route to becoming resistant, the cells take a strikingly diverse set of avenues, often several at a time. The findings, reported online today in the New England Journal of Medicine, underscore the need for new drugs that inhibit KRAS differently than current agents do.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news